Abstract
A woman with dyspnea is diagnosed with a rare mitral valve primary sarcoma. Patient underwent mechanical mitral valve replacement requiring therapeutic anticoagulation with adjuvant systemic anthracycline-based chemotherapy. The challenges of preventing thromboembolism in a new mechanical prosthesis with risk of bleeding due to cancer and/or its therapies are described.